Log in

NASDAQ:CDTXCidara Therapeutics Stock Price, Forecast & News

$3.65
-0.16 (-4.20 %)
(As of 07/31/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.59
Now: $3.65
$3.81
50-Day Range
$3.34
MA: $3.81
$4.10
52-Week Range
$1.22
Now: $3.65
$4.45
Volume210,222 shs
Average Volume216,570 shs
Market Capitalization$150.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
Cidara Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.92 million
Book Value$1.15 per share

Profitability

Net Income$-41,090,000.00

Miscellaneous

Employees68
Market Cap$150.09 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable
$3.65
-0.16 (-4.20 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

How has Cidara Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDTX stock has increased by 47.2% and is now trading at $3.65.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Cidara Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cidara Therapeutics
.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Cidara Therapeutics
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics Inc (NASDAQ:CDTX) issued its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.12. The biotechnology company had revenue of $2.53 million for the quarter, compared to the consensus estimate of $5 million.
View Cidara Therapeutics' earnings history
.

What price target have analysts set for CDTX?

5 Wall Street analysts have issued 1 year price targets for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cidara Therapeutics' stock price to reach $6.65 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.
View analysts' price targets for Cidara Therapeutics
.

Has Cidara Therapeutics been receiving favorable news coverage?

Media headlines about CDTX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Cidara Therapeutics
.

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Gilead Sciences (GILD), VBI Vaccines (VBIV), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU) and Sanofi (SNY).

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:
  • Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)
  • Dr. Taylor Sandison, Chief Medical Officer (Age 47)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)
  • Mr. James E. Levine, Chief Financial Officer (Age 48)
  • Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include UBS Group AG (0.34%), Raymond James Financial Services Advisors Inc. (0.25%) and Strs Ohio (0.04%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala.
View institutional ownership trends for Cidara Therapeutics
.

Which institutional investors are buying Cidara Therapeutics stock?

CDTX stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Raymond James Financial Services Advisors Inc., and Strs Ohio. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, and Jeffrey Stein.
View insider buying and selling activity for Cidara Therapeutics
.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $3.65.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $150.09 million and generates $20.92 million in revenue each year. The biotechnology company earns $-41,090,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.